Compare CCO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | RARE |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2005 | 2013 |
| Metric | CCO | RARE |
|---|---|---|
| Price | $2.46 | $14.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 20 |
| Target Price | $2.43 | ★ $26.79 |
| AVG Volume (30 Days) | 4.9M | ★ 5.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 22.95% | N/A |
| EPS Growth | ★ 110.81 | 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $673,000,000.00 |
| Revenue This Year | $6.61 | $13.03 |
| Revenue Next Year | $3.02 | $30.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.57 | ★ 20.13 |
| 52 Week Low | $1.37 | $12.73 |
| 52 Week High | $2.44 | $39.89 |
| Indicator | CCO | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 65.68 | 39.30 |
| Support Level | $2.34 | $13.95 |
| Resistance Level | N/A | $15.81 |
| Average True Range (ATR) | 0.04 | 0.69 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 94.20 | 47.58 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.